Prudential PLC Invests $518,000 in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Prudential PLC has acquired 4,174 shares of Jazz Pharmaceuticals PLC, valued at approximately $518,000, indicating institutional interest in the specialty pharmaceutical company.
• Jazz Pharmaceuticals reported an EPS of -$8.25 for the last quarter, missing expectations, while the company had a positive return on equity of 5.02% and a revenue of $1.05 billion.
• Analyst ratings on Jazz Pharmaceuticals are generally positive, with a consensus target price of $181.43 and 13 buy ratings compared to 2 hold ratings, indicating optimism for future growth.

Prudential PLC bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,174 shares of the specialty pharmaceutical company's stock, valued at approximately $518,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 9.4% during the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after acquiring an additional 91 shares during the period. Kendall Capital Management grew its stake in shares of Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after purchasing an additional 95 shares during the period. Quarry LP grew its stake in shares of Jazz Pharmaceuticals by 6.3% in the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after purchasing an additional 100 shares during the period. Louisiana State Employees Retirement System raised its position in Jazz Pharmaceuticals by 0.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after purchasing an additional 100 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its position in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock valued at $1,046,000 after purchasing an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on JAZZ shares. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Royal Bank Of Canada lowered their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $181.43.

Jazz Pharmaceuticals Stock Up 1.0%

NASDAQ:JAZZ traded up $1.1950 on Thursday, hitting $120.2650. The stock had a trading volume of 184,091 shares, compared to its average volume of 954,318. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock has a market cap of $7.30 billion, a P/E ratio of -17.87, a price-to-earnings-growth ratio of 7.51 and a beta of 0.34. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The firm's fifty day simple moving average is $112.24 and its two-hundred day simple moving average is $117.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the business posted $5.30 earnings per share. The firm's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.